Drug-resistant tuberculosis: Pediatric guidelines

Simple item page
dc.contributor.authorAl-Dabbagh M.
dc.contributor.authorLapphra K.
dc.contributor.authorMcGloin R.
dc.contributor.authorInrig K.
dc.contributor.authorSchaaf H.S.
dc.contributor.authorMarais B.J.
dc.contributor.authorSauve L.
dc.contributor.authorKitai I.
dc.contributor.authorKollmann T.R.
dc.date.accessioned2011-10-13T16:58:39Z
dc.date.available2011-10-13T16:58:39Z
dc.date.issued2011
dc.description.abstractDrug-resistant Mycobacterium tuberculosis (TB) infection represents a serious and growing problem. For patients infected or suspected of being infected with multidrug or extensively drug-resistant TB, several medications have to be given simultaneously for prolonged periods. Here, we review the literature on treatment and monitoring of adverse effects of pediatric drug-resistant TB therapy in a high resource, low TB burden setting. Copyright © 2011 by Lippincott Williams & Wilkins.
dc.description.versionReview
dc.identifier.citationPediatric Infectious Disease Journal
dc.identifier.citation30
dc.identifier.citation6
dc.identifier.citationhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79957998404&partnerID=40&md5=4a02e13db12734c0b2f78a809d6fafed
dc.identifier.issn8913668
dc.identifier.other10.1097/INF.0b013e31820b583d
dc.identifier.urihttp://hdl.handle.net/10019.1/16803
dc.subjectdrug-resistance
dc.subjectguidelines
dc.subjectMycobacterium tuberculosis
dc.subjecttherapy
dc.subjectamikacin
dc.subjectaminoglycoside antibiotic agent
dc.subjectaminosalicylic acid
dc.subjectciprofloxacin
dc.subjectcycloserine
dc.subjectethambutol
dc.subjectethionamide
dc.subjectgatifloxacin
dc.subjectisoniazid
dc.subjectkanamycin
dc.subjectliver enzyme
dc.subjectofloxacin
dc.subjectondansetron
dc.subjectpyrazinamide
dc.subjectquinoline derived antiinfective agent
dc.subjectstreptomycin
dc.subjectterizidone
dc.subjecttuberactinomycin
dc.subjectantibiotic prophylaxis
dc.subjectantibiotic resistance
dc.subjectbacterium culture
dc.subjectdirectly observed therapy
dc.subjectdrug blood level
dc.subjectdrug dose increase
dc.subjectdrug efficacy
dc.subjectdrug megadose
dc.subjectdrug resistant tuberculosis
dc.subjectdrug withdrawal
dc.subjectdysglycemia
dc.subjectelectrolyte disturbance
dc.subjectextensively drug resistant tuberculosis
dc.subjecthearing disorder
dc.subjecthepatomegaly
dc.subjecthuman
dc.subjecthypothyroidism
dc.subjectimmunocompetence
dc.subjectjaundice
dc.subjectliver disease
dc.subjectliver tenderness
dc.subjectliver toxicity
dc.subjectmetabolic disorder
dc.subjectmultidrug resistant tuberculosis
dc.subjectMycobacterium tuberculosis
dc.subjectnephrotoxicity
dc.subjectnonhuman
dc.subjectoptic neuritis
dc.subjectperipheral neuropathy
dc.subjectpriority journal
dc.subjectrecommended drug dose
dc.subjectreview
dc.subjectside effect
dc.subjecttreatment outcome
dc.subjecttuberculin test
dc.subjectunspecified side effect
dc.subjectvestibular disorder
dc.subjectvomiting
dc.subjectAdolescent
dc.subjectAntitubercular Agents
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectDrug Therapy, Combination
dc.subjectHumans
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectMycobacterium tuberculosis
dc.subjectPediatrics
dc.subjectTuberculosis, Multidrug-Resistant
dc.titleDrug-resistant tuberculosis: Pediatric guidelines
dc.typeReview
Files
Collections
Stellenbosch University - Scopus Publications